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Methionine Sulfoximine Resistance in Mycobacterium
tuberculosis Is Due to a Single Nucleotide
Deletion Resulting in Increased Expression
of the Major Glutamine Synthetase, GlnA1
Paul Carroll,1 Simon J. Waddell,2,* Philip D. Butcher,2 and Tanya Parish1,3
We investigated the effect of methionine sulfoximine (MetSox), a potent inhibitor of glutamine synthetase, on
Mycobacterium tuberculosis. M. tuberculosis encodes four glutamine synthetases, of which MetSox targets the type
I enzyme encoded by glnA1. Trancriptional profiling revealed that glutamate synthetase (gltB) and a type II
glutamine synthetase (glnA3) were induced after exposure to MetSox. In addition, we observed a high rate (105)
of spontaneous resistance to MetSox. All resistant strains had a single-nucleotide deletion in the 5’ region of
glnA1, and Western analysis revealed that GlnA1 expression was increased in resistant as compared with
sensitive strains. These data show thatM. tuberculosis can respond to the effect of MetSox inhibition either by up-
regulation of GlnA3 or by GlnA1. The high frequency of resistance suggests that MetSox and other compounds
specifically targeting GlnA1 are not likely to become successful anti-mycobacterial agents.
Introduction
N itrogen assimilation is a critical metabolic pathwayin Mycobacterium tuberculosis, as several of the key en-
zymes have been identified as being essential for growth or
for virulence1,5–8,11 Glutamine synthetase (GS) plays a key
role in nitrogen assimilation, as it catalyzes the ATP-depen-
dent reaction between glutamate and ammonia to generate
glutamine. M. tuberculosis has four GSs, although only
GlnA1, the major GS, appears to be required for in vitro
growth.6 Methionine sulfoximine (MetSox) is a potent in-
hibitor of GS.9 MetSox is phosphorylated by GS in the
presence of ATP, and it irreversibly binds to the active site,
thereby preventing the entry of the substrate glutamate.
MetSox inhibits the growth of M. tuberculosis in axenic cul-
ture and during intracellular infection of macrophages.4 In
addition, we recently demonstrated that MetSox-mediated
inhibition of GS activity, in combination with L-glutamine
(L-gln) supplementation, was sufficient to allow the isolation
of strains with deletions in GlnE, an adenylyl transferase
which post-transcriptionally regulates GS activity.1,8
Novel drugs are urgently required for treating M. tubercu-
losis infections; therefore, wewanted to assess whether GlnA1
inhibition was a rational approach for treatment. In order to
evaluate this, we investigated the effect of MetSox treatment
on M. tuberculosis, measuring growth inhibition, profiling
drug-exposure signatures, and defining resistance mutations.
Materials and Methods
Bacterial strains, growth media, and antibiotics
M. tuberculosis H37Rv (ATCC 25618) was grown in Mid-
dlebrook 7H9mediumplus 10% (vol/vol) oleic acid-albumin-
dextrose-catalase (OADC) supplement (Becton Dickinson)
and 0.05% (wt/vol) Tween 80 or on Middlebrook 7H10
agar plus 10% (vol/vol) OADC. Methionine sulfoximine,
L-glutamine, and D-glutamine were used as described.
Transcriptomics
M. tuberculosis H37Rv was grown to mid-log phase (day 4,
OD580 approx 0.4) and exposed to 200 mM methionine
sulfoximine for 4 and 8 hours alongside a carrier control
(100ml H2O). Mycobacterial RNA was extracted using the
GTC/Trizol method,12 DNase-treated and purified using
RNeasy columns (Qiagen). A M. tuberculosis whole genome
microarray, generated by the Bacterial Microarray Group at
1Barts & The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom.
2Centre for Infection, Division of Clinical Sciences, St. George’s University of London, London, United Kingdom.
3Infectious Disease Research Institute, Seattle, Washington.
*Present address: Brighton and Sussex Medical School, University of Sussex, Brighton, United Kingdom.
MICROBIAL DRUG RESISTANCE
Volume 17, Number 3, 2011
ª Mary Ann Liebert, Inc.
DOI: 10.1089/mdr.2010.0125
351
St. George’s (ArrayExpress accession number A-BUGS-23;
http://bugs.sgul.ac.uk/A-BUGS-23), was hybridized as de-
scribed12,13 usingM. tuberculosis genomic DNA as a common
reference. Three biological replicates of RNA derived from
MetSox-treated and control cultures were hybridized in du-
plicate. Comparative spot intensities from the images were
calculated using Imagene 5.5 (BioDiscovery) and imported
into GeneSpring GX 7.3 (Agilent Technologies) for further
analysis. These data were normalized to the 50th percentile
of all genes detected to be present on the array and filtered to
include only genes flagged to be present on 80% of the
arrays. Genes with a fold change >1.5 relative to the carrier
control were classed as differentially expressed. The
Hypergeometric probability ( p-value <0.05) was used to
identify functional categories of genes significantly over-
represented. Differentially expressed gene lists together with
fully annotated microarray data have been deposited in
BmG@Sbase (accession number: E-BUGS-112; http://bugs
.sgul.ac.uk/E-BUGS-112) and ArrayExpress (accession
number: E-BUGS-112).
Growth curves
Liquid cultures were diluted to give a starting optical
density at 580 nm (OD580) of 0.01 in 4ml of medium in 12mm
tubes. Each tube contained a magnetic stirrer and was in-
cubated at 378C on a Wheaton Biostir. OD580 readings were
taken periodically.
GlnA1 amplification
Primers GlnA1F (5’-GTAAAGGAGCATTCTGTGACG
GAA-3’) and GlnA1R (5’-ACGTCGTAGTACAGCGCG
AATT-3’) were used to amplify glnA1 and the upstream re-
gion for sequencing (product size 1,448 bp).
Western analysis of GlnA1
Cell extracts were prepared from liquid cultures. Cells
were harvested by centrifugation, washed twice in 10mM
Tris (pH 8.0), resuspended in 1ml of 10mM Tris (pH 8.0),
and added to lysing matrix B tubes (QBiogene). Cells were
disrupted using the Fastprep (QBiogene) set at speed 6.0 for
30 seconds. Samples were centrifuged for two min, and the
supernatant was recovered and filter sterilized. Protein was
quantified using a BCA kit (Pierce), and 15mg of total protein
was loaded onto 12% polyacrylamide gels and transferred to
PVDF membranes (Invitrogen) for Western blot analysis.
Membranes were probed with rat anti-GlnA1 antibody from
Ida Rosenkrands (Statens Serum Institut, Denmark). The
primary antibody was detected using horseradish peroxi-
dase goat-anti-rat (Sigma), and activity was detected using
an ECL kit (GE Healthcare).
Results
The effects of MetSox on M. tuberculosis growth
and survival
We determined the effects of MetSox on the growth of
M. tuberculosis by measuring both changes in optical den-
sity and counting viable bacilli. First, we determined that
the MIC99 of MetSox for M. tuberculosis on solid medium
was 50 mM. When treated with 200 mM, MetSox cultures
showed complete inhibition of growth, and, in fact, the
OD580 slowly decreased from 0.4 to 0.18 (Fig. 1A). Inhibi-
tion of growth was completely relieved by the addition of
3mM L-glutamine (Fig. 1B), which was expected as MetSox
treatment should have the equivalent phenotypic effects
as the deletion of glnA1, encoding glutamine synthestase,
that is, glutamine auxotrophy. We titrated the minimum
amount of L-gln required to overcome inhibition by Met-
Sox: cells were able to grow in medium containing 300 mM,
but not 30 mM L-gln. Interestingly, 3mM D-gln was not able
to rescue the cells from MetSox-dependent killing, sug-
gesting that the bacteria lack any isomerase able to convert
D-gln to L-gln.
Inhibition of growth can result from either bacteriostatic or
bactericidal effects. The decrease in OD suggested that the
bacteria were lysing, and, thus, MetSox exposure is lethal. In
order to assess this, we cultured M. tuberculosis in liquid
FIG. 1. Inhibition of Mycobacterium tuberculosis H37Rv growth by MetSox. M. tuberculosis was cultured in (A) medium only
(solid diamond) or medium plus 200 mM MetSox (open circle) and (B) medium plus 2mM MetSox (open box) or 200mM
MetSox and 3mM L-gln (filled box). Data represent the average and standard deviations of four independent cultures.
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medium containing 200mM MetSox and assayed viability by
plating serial dilutions (Fig. 2). In the presence of 200mM
MetSox, the numbers of viable bacteria decreased by almost
two logs (3.57105 to 9.07103) in 24 hours. In contrast, the
M. tuberculosis control (no MetSox) and rescued cultures
(MetSox plus L-gln) showed a 2-fold increase in viability,
due to cell multiplication. These data show that MetSox has a
rapid effect on cell viability (within 24 hours), although cells
do not immediately lyse, as the OD remains the same over
the short time period assayed.
The M. tuberculosis transcriptional signature
to MetSox exposure
The M. tuberculosis response to the early effects of gluta-
mine synthetase inhibition was determined by treating log
phase axenic cultures with 200 mM MetSox and profiling the
global gene expression patterns 4 and 8 hours after exposure.
The transcriptional response to MetSox was limited, with no
genes >3-fold differentially regulated relative to the carrier
control at 4 or 8 hours. 60 genes were >1.5-fold differentially
expressed after 4 hours of MetSox exposure, and the same
with regard to 72 genes after 8 hours. The functional cate-
gory 1.D.1 Glutamate Family, including genes involved in
the metabolism of glutamine/glutamate,2 was significantly
enriched in the subset of genes induced after MetSox expo-
sure at 4 or 8 hours (Fig. 3). Specifically, gltB coding for
glutamate synthase and glnA3 encoding glutamine synthe-
tase 3 were induced reflecting the changing pool of nitrogen
intermediates available on inhibition of glnA1. Rv1879
directly downstream of glnA3 was also up-regulated by
MetSox treatment. The induction of glnA3 may reveal a
compensatory function for this alternative glutamine syn-
thetase or highlight different mechanisms of regulatory
control, with glnA3 transcriptionally induced in response to
loss of GS function; whereas glnA1 is regulated primarily at
the post-translational level. Interestingly, genes in the func-
tional category I.B.7 encompassing miscellaneous oxidore-
ductases and oxygenases2 were also significantly over-
represented in the subset of genes induced by MetSox
treatment. This may constitute the weak inhibition of gshA,
encoding a glutamate-cysteine ligase, that disrupts myco-
bacterial redox potential.6
Identification and characterization
of MetSox resistant mutants
During the course of these experiments, we noted the
appearance of spontaneous resistant mutants. When bacilli
from liquid cultures containing MetSox were plated onto
200mM MetSox, we routinely observed low numbers of vi-
able colonies. Cells plated from the viability experiment were
used to estimate the frequency of resistance; from the initial
2.7105 inoculum, 32 colonies were isolated on MetSox
medium, giving a resistance frequency of 105. Twelve
strains were further analyzed. Resistance was confirmed by
streaking these strains onto MetSox-containing solid me-
dium. All twelve strains grew on plates containing 100, 200,
and 400mM MetSox, confirming that these strains were truly
resistant to MetSox. Wild-type M. tuberculosis did not grow
when streaked onto plates containing MetSox unless L-gln
was added.
Since the MetSoxR strains isolated were not auxotrophic
for L-gln, it indicated that a functional GS was still present.
Given the high frequency of spontaneous mutation, we de-
cided to determine the mechanism of resistance to MetSox.
We focused on the major type I GS, GlnA1, as it seemed the
most likely target of MetSox action and, thus, might harbor
resistance-conferring mutations. We sequenced the glnA1
gene from eight resistant strains. We discovered a single
nucleotide deletion located in the proposed coding region of
FIG. 2. MetSox-mediated killing of M. tuberculosis. M.
tuberculosis H37Rv was cultured in medium only (solid
square); 200mM MetSox (solid triangle); 200 mM MetSox,
3mML-Gln (open circle). Viability wasmeasured by counting
CFUs. Data represent the average and standard deviations for
three independent cultures.
FIG. 3. MetSox-mediated changes in the regulation of
glutamate metabolism. M. tuberculosis was exposed to
200mM MetSox for 4 or 8 hours; global gene expression
profiles were determined by competitive hybridization of
RNA to genomic DNA using whole genome microarrays.
The relative levels of expression for each gene were deter-
mined and normalized to the control (untreated) population.
The gene expression pattern of the 1.D.1 glutamate metab-
olism family of genes2 is shown; four key genes are marked.
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glnA1 at þ33 relative to the translational start site (genome
position 2487647) in all the resistant strains analyzed (Fig. 4).
This deletion would potentially lead to a frameshift mutation
inactivating the protein. However, sequence analysis re-
vealed a second potential translation start site, which would
produce a 447 amino acid protein lacking the first 31 amino
acids of the predicted full length GlnA1. Thus, we hypoth-
esized that either the strains were producing a truncated
protein with full GS activity or the translation start site of the
protein is misannotated in the Tuberculist database (http://
genolist.pasteur.fr/TubercuList/index.html) (Fig. 4). In or-
der to examine these two possibilities, we investigated
GlnA1 expression in the wild-type and MetSoxR strains. Cell-
free extracts were generated from aerated liquid cultures and
Western analysis carried out with an antibody generated to
M. tuberculosis GlnA1. These data indicated that all MetSoxR
strains expressed GlnA1 of the same apparent size as the
wild-type strain. However, they all showed an increased
level of expression of GlnA1, in comparison to the wild-type
strain (Fig. 5). An unknown protein band at a higher mo-
lecular weight than GlnA1 was also present in the MetSoxR
cell extracts.
Discussion
We investigated the role of the potent GS inhibitor MetSox
on both the transcriptome and growth of M. tuberculosis.
Global expression analyses suggest that M. tuberculosis re-
sponds to MetSox exposure and the inhibition of GS activity
by increasing transcription of several genes involved in ni-
trogen assimilation. Of these, GlnA3 is one of the four GS
encoded by M. tuberculosis (GlnA1-4) and, similar to GlnA1,
is involved in the synthesis of L-gln.6 However, GlnA3 is a
heat-labile type II GS that is not post-translationally con-
trolled by adenylylation, in contrast to the heat stable type I
GS, GlnA1, controlled by adenlylyation.3,10 It is, therefore,
plausible that GlnA3 expression increases in response to a
decrease in the glutamine pool due to GlnA1 inactivation.
Interestingly, expression of GltB, which encodes glutamate
synthesis and is part of the GOGAT pathway, was increased.
This suggests that GlnA3 is replacing the role of GlnA1; but,
since activity cannot be regulated post-transcriptionally,
similar to GlnA1, glutamine is being converted back to glu-
tamate by GltB to regulate the internal nitrogen pool. A high
frequency of spontaneous resistance was observed after
MetSox exposure. All resistant strains had a single bp dele-
tion downstream of the annotated translational start site.
However, a second start site was located 93 bases from
the original. Western analysis revealed that GlnA1 was
still translated, leading us to conclude that the second
translational start site is active and that the resistance-
conferring deletion is in the upstream region either within
the GlnA1 promoter or within a regulatory site. Thus, the
single-nucleotide deletion conferring MetSox-resistance like-
FIG. 4. Identification of a single base deletion in the upstream region of glnA1 in MetSox resistant strains. The upstream
region of glnA1 is indicated. The upstream region and coding sequence of the resistant isolates were determined. The single
nucleotide (A) that was deleted in all the MetSoxR strains is boxed and indicated in bold. The two identified transcriptional
start sites are denoted with curved arrows; potential translational start sites, promoter regions (10 and 35), the s60 binding
site, and Shine-Dalgarno (SD) sites are all indicated.
FIG. 5. Expression of GlnA1 in MetSox resistant strains.
Cell-free extracts were prepared from wild-type and Met-
SoxR strains grown under aerated conditions for 1 week.
15 mg of total protein was analyzed by (A) SDS-PAGE and
(B) Western blotting. (A) Gels were stained with SimplyBlue
(Invitrogen). Protein molecular marker sizes are displayed;
the arrow indicates the approximate location of GlnA1
(57 kDa). (B)Western blotting was carried out with a GlnA1-
specific antibody. Lanes 1–3: wild-type H37Rv; Lanes 4–6:
three independent MetSoxR strains.
354 CARROLL ET AL.
ly disrupts the regulation of glutamine synthetase, thereby
resulting in increased GlnA1 expression.
Since MetSox resistance was easily generated by over-
expression of the target GlnA1, it is likely that other inhibitors
targeting the same enzyme would also result in resistance.
Thus,we suggest thatGlnA1 is not a suitable antimycobacterial
drug target in the search for novel therapeutic agents.
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